Femasys (FEMY)
(Real Time Quote from BATS)
$1.29 USD
-0.04 (-3.01%)
Updated Apr 26, 2024 02:24 PM ET
4-Sell of 5 4
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Femasys Inc. [FEMY]
Reports for Purchase
Showing records 1 - 17 ( 17 total )
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
FemaSeed Leads to 24% Pregnancy Rate in Severe Infertility Subgroup
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
Strategic Financing to Extend Cash Runway Into 2H25 and Provide Funding For FemaSeed Commercial Launch in Early 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Recap: We Expect FemaSeed Launch Preparations to Initiate Shortly, Followed by Commercialization in 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
FemaSeed Approval Clears Path Toward Launch in Early 2024; Increasing PT to $13
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Recap: FINALE Pivotal Study For FemBloc Has Been Initiated
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
FemBloc IDE Approved With Pivotal Trial Set to Initiate in 3Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Recap: FemaSeed Pivotal Data on Track for Mid-2023 and FemBloc IDE Approval Could be Very Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
Noteworthy Discussion Points From Our Meetings at
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Take: Multiple Catalysts Planned for 2023 Including FemBloc Pivotal Study Initiation and FemaSeed Pivotal Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
FemaSeed Focus Is Now On Male Factor Infertility; Lowering PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
FemCerv Commercial Availability Could Add Additional Near-Term Revenue
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Take: All Timelines Remain on Track; We Expect FemaSeed Interim Data in 4Q22 to Be a Significant Catalyst
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
FemBloc''s Advantages Could Position It to Be the Preferred Permanent Birth Control Solution
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Take: Focus Remains on 4Q22 FemaSeed Interim Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
4Q21 Take: FemaSeed Interim Data in 4Q22 Could Be a Significant De-Risking Event
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
Two Ends of the Reproductive Health Spectrum, One Device; Initiate at Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
|